Interferon impedes an early step of hepatitis delta virus infection

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Han, Ziying ^a   Nogusa, Shoko ^a   Nicolas, Emmanuelle ^a   Balachandran, Siddharth ^a   Taylor, John ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; GAMMA INTERFERON; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN KINASE R; PROTEIN MX1; PROTEIN MX2; PROTEIN MX3; RECOMBINANT ALPHA2B INTERFERON; STAT1 PROTEIN; UNCLASSIFIED DRUG; VIRUS RNA; ALPHA INTERFERON; PEPTIDE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DELTA AGENT HEPATITIS; DRUG EFFICACY; DRUG MECHANISM; GENETIC TRANSFECTION; HEPATITIS DELTA VIRUS; HUMAN; HUMAN CELL; LIVER CELL; NONHUMAN; TREATMENT RESPONSE; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS INHIBITION; VIRUS REPLICATION; CELL CULTURE; CELL STRAIN HEK293; DRUG EFFECT; METABOLISM; PHYSIOLOGY; TIME; VESICULAR STOMATITIS VIRUS; VIROLOGY;

HEPATITIS DELTA VIRUS;

CELLS, CULTURED; HEK293 CELLS; HEPATITIS D; HEPATITIS DELTA VIRUS; HEPATOCYTES; HUMANS; INTERFERON-ALPHA; INTERFERON-GAMMA; PEPTIDES; POLY I-C; TIME FACTORS; TRANSFECTION; VESICULOVIRUS; VIRUS REPLICATION;

EID: 79960442858     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022415     Document Type: Article

References (31)

1. Rizzetto M, Canese MG, Arico J, Crivelli O, Bonino F, et al. (1977) Immunofluorescence detection of a new antigen-antibody system associated to the hepatitis B virus in the liver and in the serum of HBsAg carriers. Gut 18: 997-1003.
2. Taylor JM, Farci P, Purcell RH, (2007) Hepatitis D (delta) virus. In: Knipe DM, editors. Fields Virology. Fifth ed Philadelphia Lippincott Williams & Wilkins pp. 3031-3046.
3. Rizzetto M, Verme G, Recchia S, Bonino F, Farci P, et al. (1983) Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med 98: 437-441.
4. Wedemeyer H, Manns MP, (2010) Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 7: 31-40.
5. Wedemeyer H, (2010) Re-emerging interest in hepatitis delta: new insights into the dynamic interplay between HBV and HDV. J Hepatol 52: 627-629.
6. Farci P, (2011) Hepatitis D. In: Dooley JS, Lok ASF, Burroughs AK, Heathcote EJ, editors. Sherlock's Diseases of the Liver and Biliary System. Twelfth ed Blackwell pp. 393-405.
7. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, et al. (2011) Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 364: 322-331.
8. Chang J, Nie X, Gudima S, Taylor J, (2006) Action of inhibitors on accumulation of processed hepatitis delta virus RNAs. J Virol 80: 3205-3214.
9. McNair ANB, Monjardino J, Cheng D, Thomas HC, Kerr IM, (1993) Hepatitis delta virus and the interferon system. Prog Clin Biol Res 382: 161-164.
10. Ilan YM, Klein A, Taylor J, Tur-Kaspa R, (1992) Resistance of hepatitis delta virus replication to alpha interferon treatment in transfected human cells. J Infect Dis 166: 1164-1166.
11. Pugnale P, Pazienza V, Guilloux K, Negro F, (2009) Hepatitis delta virus inhibits alpha interferon signaling. Hepatology 49: 398-406.
12. Chang J, Gudima SO, Tarn C, Nie X, Taylor JM, (2005) Development of a novel system to study hepatitis delta virus genome replication. J Virol 79: 8182-8188.
13. Taylor JM, (2011) Viral Hepatitis D. In: Monga SPS, editors. Molecular Pathology of Liver Diseases New York Springer+Business Media pp. 589-595.
14. Guo H, Jiang D, Ma D, Chang J, Dougherty AM, et al. (2009) Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol 83: 847-858.
15. Gudima S, He Y, Meier A, Chang J, Chen R, et al. (2007) Assembly of hepatitis delta virus: particle characterization, including the ability to infect primary human hepatocytes. J Virol 81: 3608-3617.
16. Glebe D, Urban S, (2007) Viral and cellular determinants involved in hepadnaviral entry. World J Gastroenterol 13: 22-38.
17. Barrera A, Guerra B, Notvall L, Lanford RE, (2005) Mapping of the hepatitis B virus pre-S1 domain involved in receptor recognition. J Virol 79: 9786-9798.
18. Urban S, (2008) New insights into hepatitis B and hepatitis delta virus entry. Future Virol 3: 253-264.
19. Gripon P, Cannie I, Urban S, (2005) Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol 79: 1613-1622.
20. Petersen J, Dandri M, Mier W, Lutgehetmann M, Volz T, et al. (2008) Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 26: 335-341.
21. van Boxel-Dezaire AH, Rani MR, Stark GR, (2006) Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 25: 361-372.
22. van Boxel-Dezaire AH, Zula JA, Xu Y, Ransohoff RM, Jacobberger JW, et al. (2010) Major differences in the responses of primary human leukocyte subsets to IFN-beta. J Immunol 185: 5888-5899.
23. van Boxel-Dezaire AH, Stark GR, (2007) Cell type-specific signaling in response to interferon-gamma. Curr Top Microbiol Immunol 316: 119-154.
24. Taylor JM, Han Z, (2010) Purinergic receptor functionality is necessary for infection of human hepatocytes by hepatitis delta virus and hepatitis B virus. PLos ONE 5: 1-5.
25. Agrawal S, Kandimalla ER, (2007) Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem Soc Trans 35: 1461-1467.
26. Bordier BB, Marion PL, Ohashi K, Kay MA, Greenberg HB, et al. (2002) A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. J Virol 76: 10465-10472.
27. Chang J, Taylor JM, (2003) Susceptibility of human hepatitis delta virus RNAs to small interfering RNA action. J Virol 77: 9728-9731.
28. Shaw G, Morse S, Ararat M, Graham FL, (2002) Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J 16: 869-871.
29. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J, (1982) Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Canc Res 42: 3858-3863.
30. Fernandez M, Porosnicu M, Markovic D, Barber GN, (2002) Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol 76: 895-904.
31. Balachandran S, Kim CN, Yeh WC, Mak TW, Bhalla K, et al. (1998) Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling. EMBO J 17: 6888-6902.